. pfizer Gains Option to Buy RareDisease GeneTherapy Developer Vivettx for Up to $687M httpow.ly8qWs30o7xKxÂpic.twitter.comD5QV1HCFHk
. @pfizer Gains Option to Buy #RareDisease #GeneTherapy Developer @Vivet_tx for Up to $687M: http://ow.ly/8qWs30o7xKx pic.twitter.com/D5QV1HCFHk
More From BioPortfolio on ". @pfizer Gains Option to Buy #RareDisease #GeneTherapy Developer @Vivet_tx for Up to $687M: http://ow.ly/8qWs30o7xKx pic.twitter.com/D5QV1HCFHk"